text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 82640-04-8 | Product Number: R0109

Raloxifene Hydrochloride


Purity: >98.0%(T)(HPLC)
Synonyms:
  • [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
Documents:
1G
€212.00
2   ≥20 
5G
€641.00
Contact Us 2  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number R0109
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__2__8H__2__7NO__4S·HCl = 510.05  
Physical State (20 deg.C) Solid
CAS RN 82640-04-8
Related CAS RN 84449-90-1
Reaxys Registry Number 6036780
PubChem Substance ID 172089090
Merck Index (14) 8098
MDL Number

MFCD01938233

Specifications
Appearance Light yellow to Yellow to Green powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Nonaqueous Titration) min. 98.0 %
Properties (reference)
Melting Point 263 °C
Maximum Absorption Wavelength 286 nm
GHS
Pictogram Pictogram
Signal Word Warning
Hazard Statements H361 : Suspected of damaging fertility or the unborn child.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P202 : Do not handle until all safety precautions have been read and understood.
P201 : Obtain special instructions before use.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
P405 : Store locked up.
Related Laws:
RTECS# PC4956925
Transport Information:
HS Number 2934999090
Application
Raloxifene Hydrochloride: Selective Estrogen Receptor Modulator (SERM)

Raloxifene hydrochloride is a nonsteroidal estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). Raloxifene is a therapeutic agent for postmenopausal osteoporosis, and also is indicated for the reduction in risk of invasive breast cancer in postmenopausal women. The biological actions are mediated through binding to estrogen receptors in the cell nucleus. This binding results in activation of estrogenic pathways in bone (agonism) and blockade of estrogenic pathways in breast and uterus (antagonism). (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number Incorrect Lot Number is entered

The requested analytical chart is not available. Sorry for the inconvenience.

Other Documents